Orgenesis Stock Today

ORGS -  USA Stock  

USD 4.78  0.13  2.65%

Orgenesis is selling at 4.78 as of the 28th of July 2021; that is -2.65 percent down since the beginning of the trading day. The stock's lowest day price was 4.76. Orgenesis has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for Orgenesis are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 28th of June 2021 and ending today, the 28th of July 2021. Click here to learn more.
 Market Performance
1 of 100
  Odds Of Distress
Over 90
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

Orgenesis Stock Profile

Orgenesis Inc., a biotech company, focusing on cell and gene therapies . The company was incorporated in 2008 and is based in Germantown, Maryland. Orgenesis operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 111 people. more on Orgenesis
Orgenesis has very high historical volatility over the last 90 days
Orgenesis has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 15.16 M. Net Loss for the year was (83.17 M) with profit before overhead, payroll, taxes, and interest of 7.65 M.
Orgenesis currently holds about 41.84 M in cash with (68.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.71.
Latest headline from Would Shareholders Who Purchased Orgenesis Stock Three Years Be Happy With The Share price Today - Yahoo Finance
Legal NameOrgenesis
CEO of Orgenesis Maryland IncScott Carmer  (View All)
Average Analyst Recommendation
Analysts covering Orgenesis report their recommendations after researching Orgenesis' financial statements, talking to executives and customers, or listening in on Orgenesis' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Orgenesis. The Orgenesis consensus assessment is calculated by taking the average forecast from all of the analysts covering Orgenesis.
Strong Buy1 Opinion
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Orgenesis' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong SellUndervalued
Orgenesis (ORGS) is traded on NASDAQ Exchange in USA and employs 111 people. The company currently falls under 'Small-Cap' category with current market capitalization of 117.01 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Orgenesis's market, we take the total number of its shares issued and multiply it by Orgenesis's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Orgenesis conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 24.48 M outstanding shares of which 1.83 M shares are now shorted by private and institutional investors with about 11.1 trading days to cover. Orgenesis currently holds about 41.84 M in cash with (68.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.71.
Check Orgenesis Probability Of Bankruptcy
Orgenesis owns a total of twenty-four million four hundred eighty thousand outstanding shares. Orgenesis holds 5.47 pct. if its outstanding shares held by insiders and 5.47 pct. owned by third-party entities . Please note that no matter how much assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.

Ownership Allocation (%)

Check Orgenesis Ownership Details

Orgenesis Stock Price Odds Analysis

What are Orgenesis' target price odds to finish over the current price? In regard to a normal probability distribution, the odds of Orgenesis jumping above the current price in 90 days from now is about 57.5%. The Orgenesis probability density function shows the probability of Orgenesis stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Orgenesis has a beta of 0.2354. This indicates as returns on the market go up, Orgenesis average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Orgenesis will be expected to be much smaller as well. Additionally, the company has an alpha of 0.1264, implying that it can generate a 0.13 percent excess return over DOW after adjusting for the inherited market risk (beta).
 Odds Down 4.78HorizonTargetOdds Up 4.78 
42.41%90 days
Based on a normal probability distribution, the odds of Orgenesis to move above the current price in 90 days from now is about 57.5 (This Orgenesis probability density function shows the probability of Orgenesis Stock to fall within a particular range of prices over 90 days) .

Orgenesis Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. Orgenesis market risk premium is the additional return an investor will receive from holding Orgenesis long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Orgenesis. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Orgenesis' alpha and beta are two of the key measurements used to evaluate Orgenesis' performance over the market, the standard measures of volatility play an important role as well.

Orgenesis Stock Against Markets

Picking the right benchmark for Orgenesis stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Orgenesis stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Orgenesis is critical whether you are bullish or bearish towards Orgenesis at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Orgenesis without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Price Exposure Probability Now


Price Exposure Probability

Analyze equity upside and downside potential for a given time horizon across multiple markets
All  Next Launch Module

Orgenesis Corporate Directors

Orgenesis corporate directors refer to members of an Orgenesis board of directors. The board of directors generally takes responsibility for the Orgenesis' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Orgenesis' board members must vote for the resolution. The Orgenesis board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Please check Your Equity Center. Note that the Orgenesis information on this page should be used as a complementary analysis to other Orgenesis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Complementary Tools for Orgenesis Stock analysis

When running Orgenesis price analysis, check to measure Orgenesis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orgenesis is operating at the current time. Most of Orgenesis' value examination focuses on studying past and present price action to predict the probability of Orgenesis' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Orgenesis' price. Additionally, you may evaluate how the addition of Orgenesis to your portfolios can decrease your overall portfolio volatility.
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Fundamental Analysis
View fundamental data based on most recent published financial statements
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
The market value of Orgenesis is measured differently than its book value, which is the value of Orgenesis that is recorded on the company's balance sheet. Investors also form their own opinion of Orgenesis' value that differs from its market value or its book value, called intrinsic value, which is Orgenesis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orgenesis' market value can be influenced by many factors that don't directly affect Orgenesis underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Orgenesis' value and its price as these two are different measures arrived at by different means. Investors typically determine Orgenesis value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orgenesis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.